[Leish-l] RES: testing vaccinated dogs for immunopotentiation
mauro.marzochi at ipec.fiocruz.br
mauro.marzochi at ipec.fiocruz.br
Mon Oct 24 18:12:28 BRST 2011
I agree with Dr. Chang that in the case of USA and Canada (Duprey et
al, 2006), in the absence of transmission of CVL by sand flies, all the
emphasis was given to transmission dog to dog by biting, reusing needles
for injections, blood transfusion and breeding. Never raise the
possibility of oral transmission by sharing food.
However, I also agree with Carlos that the study of oral transmission,
if important, can serve as a model for the assessment of the importance
of dog asymptomatic and effectiveness of vaccines in the transmission of
CVL.
Mauro C A MarzochiIPEC-Fiocruz/CNPq
On Sat, 22 Oct 2011 14:47:57 -0500, Chang, Kwang-Poo wrote:
> Dear Carlos,
>
> Most interesting information and thoughts !
>
> I have not come across publications about recovery of Leishmania from
> human and animal genital/oral mucosa. This may be inferred from
> published records on the transmission of leishmaniasis via sexual
> activities and blood transfusion in humans and dogs. Transmission
> via these and congenital routes have always been considered as very
> rare, except perhaps for the canine leishmaniasis in the USA.
>
> The zoonotic aspects of epidemiology in leishmaniasis are most
> interesting and highly significant, but are difficult to study
> because
> it requires lots of funding for long-term investigation. Brazil is
> undoubtedly the place for such study, and Jeff and Sinval have
> contributed significantly to this area. Sylvatic rodent, edentate
> and canine cycles of transmission are already very complicated. It
> would be even more complicated, should there be intersection among
> the
> 3 cycles and the involvement of domestic dogs, as stated in your
> message, regardless of vector or non-vector transmission. That makes
> the rat-rat, pig-pig and pig-rat cycles of transmission in
> trichinosis
> very simple by comparison.
>
> KP
>
> -------------------------
>
> FROM: Carlos Costa [mailto:chncosta at gmail.com]
> SENT: Saturday, October 22, 2011 8:14 AM
> TO: Chang, Kwang-Poo
> CC: mauro.marzochi at ipec.fiocruz.br; leish-l at lineu.icb.usp.br
> SUBJECT: Re: [Leish-l] RES: testing vaccinated dogs for
> immunopotentiation
>
> Dear KP,
>
> Leishmania can be recovered from genital & oral mucosa or secretions
> from humans and animals. Direct transmission has been documented via
> blood transfusion, sex and vertical in humans and dogs. So, it
> exists.
> The question reside in is its magnitude and importance.
>
> It took me a few days to respond to your call because I was searching
> my older references looking for a particular one, actually an
> abstract
> of a meeting, showing that if you put one infected hamster in sand
> fly-proof free cage, with time most will get infected. Hopefully one
> of you will find it (or do it again), since I could not find mine.
>
> Months ago, talking to Dr. Sinval Brandão-Filho, the next host of
> WorldLeish, we wondered if a low prevalence rodent cycle could not
> feed a dog cycle and thereafter human transmission. It sounds logic
> if, and only if, in fact there is a rodent cycle (some data suggest
> it
> does not, but others (Jeff Shaw's) that it does - any way, this a
> critical point). The logic is that canids feed a lot on rodents (and
> on opossums), and are very vulnerable, and go back to human
> dwellings.
> The same would be valid for a purely sylvatic cycle among
> rodents/opossums and foxes).
>
> Of course, rodents may not be required if oral transmission among
> dogs
> is possible and common, as American, Canadian and Dutch kennel data
> suggest. But since there is a large overlap between the presence of
> sandflies and zoonotic kala-azar in endemic countries such a
> transmission may have a limited role and may be restricted to animals
> that are confined in groups or to stray dogs and sylvatic canids, but
> not to solitary animals restricted to households.
>
> Any way, this a largely under investigated subject, which can bring
> surprises to the presently established & dominating knowledge.
> Deserves a lot of funding.
>
> One last note: if it shows to be indeed important, sandfly challenge
> may not be required for vaccine evaluation.
>
> Cheers,
>
> Carlos.
>
> 2011/10/21 Chang, Kwang-Poo
>
> Carlos Costa brought my attention to this possibility as well. Carlos
> may want to comment on this ? Is this a hypothesis based on common
> sense or on observation/experimental data ?
>
> KP
>
> -----Original Message-----
> From: leish-l-bounces at lineu.icb.usp.br [2]
> [mailto:leish-l-bounces at lineu.icb.usp.br [3]] On Behalf Of
> mauro.marzochi at ipec.fiocruz.br [4]
> Sent: Wednesday, October 19, 2011 2:26 PM
> To: leish-l at lineu.icb.usp.br [5]
> Subject: Re: [Leish-l] RES: testing vaccinated dogs for
> immunopotentiation
>
> Dear All,
> In the past, it was believed that in the Mediterranean region the
> visceral leishmaniasis transmission to children could be attributed
> to
> contamination of healthy children by the saliva of dogs infected
> with
> Leishmania infantum (Alencar?; Hommel?). Thus, the inter canine
> transmission in confined environments could not be established by
> the
> contamination of food shared between infected and uninfected dogs?
>
> Mauro C A Marzochi
> IPEC-Fiocruz/CNPq
>
> On Wed, 19 Oct 2011 08:25:45 -0500, Petersen, Christine A [V PTH]
> wrote:
> > Dear all-
> > Thanks for the review. Vertical infection is maintaining infection
> > in dogs in the United States. We continue to look for vector
> > transmission, and despite having potential sand fly vectors, no
> > infected flies to date.
> > Christy Petersen
> > -----Original Message-----
> > From: leish-l-bounces at lineu.icb.usp.br [6]
> > [mailto:leish-l-bounces at lineu.icb.usp.br [7]] On Behalf Of
> Courtenay,
> > Orin
> > Sent: Wednesday, October 19, 2011 3:46 AM
> > To: leish-l at lineu.icb.usp.br [8]; jayusp at hotmail.com [9]
> > Subject: Re: [Leish-l] RES: testing vaccinated dogs for
> > immunopotentiation
> >
> > Dear all,
> > I attach a recent review of evidence for non-sandfly transmission
> > routes and cycles in different hosts.
> >
> > It is worth distinguishing between vaccination outcomes: one that
> > provides individual protection versus one that provides community
> > protection (herd immunity) by interrupting the transmission cycle
> > (R0 unlikely to maintain transmission independent of the
> dog-sandfly-dog
> > cycle.
> >
> > Orin
> >
> >
> > Dr. Orin Courtenay
> > Reader
> > School of Life Sciences
> > University of Warwick
> > Gibbet Hill Road
> > Coventry
> > CV4 7AL
> > ++44 +2476 524550
> > skype: orin.courtenay
> > orin.courtenay at warwick.ac.uk [10]
> > http://www2.warwick.ac.uk/fac/sci/lifesci/people/ocourtenay/ [11]
> >
> > Emails over 10Mb will not reach me. If you want to send large
> files
> > use the following:
> https://files.warwick.ac.uk/orincourtenay/sendto
> [12]
> >
> >
> >
> > -----Original Message-----
> > From: leish-l-bounces at lineu.icb.usp.br [13]
> > [mailto:leish-l-bounces at lineu.icb.usp.br [14]] On Behalf Of Chang,
> > Kwang-Poo
> > Sent: 17 October 2011 18:54
> > To: Patrick Bastien; leish-l at lineu.icb.usp.br [15]
> > Subject: Re: [Leish-l] RES: testing vaccinated dogs for
> > immunopotentiation
> >
> > Dear Patrick,
> >
> > Thanks a lot for the article from Brazil about vertical
> transmission
> > of canine leishmaniasis. The work is significant and was done by
> > examining stillborn pups.
> >
> > Christy's recent paper extended this and the other earlier finding
> of
> > Leishmania in fetus to live pups. Together, they constitute strong
> > evidence for vertical transmission of Leishmania in dogs. As
> pointed
> > out in the article, its potential significance in epidemiology
> awaits
> > further study. This is also true for its implication in
> considering
> > vaccination, etc.
> >
> > KP
> >
> >
> >
> > -----Original Message-----
> > From: leish-l-bounces at lineu.icb.usp.br [16]
> > [mailto:leish-l-bounces at lineu.icb.usp.br [17]] On Behalf Of
> Patrick
> > Bastien
> > Sent: Saturday, October 15, 2011 3:13 AM
> > To: leish-l at lineu.icb.usp.br [18]
> > Subject: Re: [Leish-l] RES: testing vaccinated dogs for
> > immunopotentiation
> >
> > Dear KP,
> > That's it for article [3].
> > (don't ask me how I got this proof, I cant' remember).
> > Best wishes
> > P. Bastien
> >
> > Professeur Patrick Bastien
> > Laboratoire de Parasitologie-Mycologie, Faculté de Médecine UMR
> > MIVEGEC (CNRS 5290 - IRD 224 - Université Montpellier 1) Centre
> > National de Référence des Leishmania CHU de Montpellier
> > 39 Avenue Charles Flahault
> > 34295 Montpellier Cedex 5, France
> >
> > "Chang, Kwang-Poo" a écrit :
> >
> >> I also recall the description of sexual transmission in human
> >> leishmaniasis in old literature, but this is rare.
> >>
> >>
> >> Going back to the issue of congenital transmission in human and
> >> canine leishmaiasis, I listed 3 articles below from a pubmed
> search.
> >>
> >> [1] Pediatrics. 1999 Nov;104(5):e65.
> >> Congenital transmission of visceral leishmaniasis (Kala Azar)
> from
> >> an asymptomatic mother to her child.
> >> Meinecke CK, Schottelius J, Oskam L, Fleischer B.
> >> SourceChildren's Hospital of Stuttgart (Olgahospital), Stuttgart,
> >> Germany.
> >>
> >>
> >>
> >> [2] J Parasitol. 2005 Aug;91(4):970-2.
> >> Transplacental transmission of a North American isolate of
> >> Leishmania infantum in an experimentally infected beagle.
> >> Rosypal AC, Troy GC, Zajac AM, Frank G, Lindsay DS.
> >> SourceDepartment of Biomedical Sciences and Pathobiology,
> >> Virginia-Maryland Regional College of Veterinary Medicine,
> Virginia
> >> Tech, Blacksburg, Virginia 24061, USA
> >>
> >> [3] Vet Parasitol. 2009 Dec 3;166(1-2):159-62. Epub 2009 Aug 15.
> >> First report of vertical transmission of Leishmania (Leishmania)
> >> infantum in a naturally infected bitch from Brazil.
> >> da Silva SM, Ribeiro VM, Ribeiro RR, Tafuri WL, Melo MN,
> Michalick
> >> MS.
> >> SourceDepartamento de Parasitologia, Instituto de Ciências
> >> Biológicas, Universidade Federal de Minas Gerais, 31270-901 Belo
> >> Horizonte, MG, Brazil.
> >>
> >> I hope Dr. Rosypal and the authors of article [3] could make the
> pdf
> >> reprints of their articles available, since they were published
> in
> >> journals, which are not readily available.
> >>
> >>
> >>
> >> KP
> >>
> >> -----Original Message-----
> >> From: leish-l-bounces at lineu.icb.usp.br [20]
> >> [mailto:leish-l-bounces at lineu.icb.usp.br [21]] On Behalf Of
> Christopher
> >> Peacock
> >> Sent: Sunday, October 09, 2011 10:33 PM
> >> To: leish-l at lineu.icb.usp.br [22]
> >> Subject: Re: [Leish-l] RES: testing vaccinated dogs for
> >> immunopotentiation
> >>
> >> Hi,
> >> There is also this rather bizarre story of a Gulf War veteran who
> >> returned with leishmaniasis, this link is a Veterans association
> >> website and suggest both sexual transmission and vertical
> >> transmission. Not sure how reliable this information is but it
> does
> >> seem to be contested in court. Would be interesting to know more
> >> details on this case and whether it has any evidence to support
> the
> >> cases, as far as I am aware there has only been one suggested
> case
> >> of sexually transmitted Leishmania in humans documented many
> years
> >> ago.
> >>
> >> http://www.vawatchdog.org/07/nf07/nfJUN07/nf062907-3.htm [23]
> >>
> >> http://www.leishmaniasis.us/Leish.html [24]
> >>
> >> Cheers
> >>
> >> Chris
> >>
> >> Associate Professor Christopher Peacock
> >> Discipline of Microbiology & Immunology M502
> >> School of Biomedical, Biomolecular & Chemical Sciences
> >> The University of Western Australia
> >> Nedlands WA 6009
> >>
> >> ph 00 61(0)8 9287 6172
> >> fax 00 61(0)8 9346 2912
> >>
> >> -----Original Message-----
> >> From: leish-l-bounces at lineu.icb.usp.br [25]
> >> [mailto:leish-l-bounces at lineu.icb.usp.br [26]] On Behalf Of
> Patrick
> >> Bastien
> >> Sent: Saturday, 8 October 2011 1:31 AM
> >> To: leish-l at lineu.icb.usp.br [27]
> >> Subject: Re: [Leish-l] RES: testing vaccinated dogs for
> >> immunopotentiation
> >>
> >> There were several earlier reports of this vertical transmission,
> >> even
> >> in the US: among others, Rosypal AC, J.Parasitol. 2005, 970-972
> and
> >> 113-115 Magno da Silva, Vet Parasitol 2009 Pangrazio, Vet
> Parasitol
> >> 2009
> >>
> >> Best regards
> >> P. Bastien
> >>
> >> Professeur Patrick Bastien
> >> Laboratoire de Parasitologie-Mycologie, Faculté de Médecine UMR
> >> MIVEGEC (CNRS 5290 - IRD 224 - Université Montpellier 1) Centre
> >> National de Référence des Leishmania CHU de Montpellier
> >> 39 Avenue Charles Flahault
> >> 34295 Montpellier Cedex 5, France
> >>
> >> "Chang, Kwang-Poo" a écrit :
> >>
> >>> What Jenni said indicates that transplacental transmission of
> >>> canine
> >>> leishmaniasis has some implication in considering dog
> vaccination.
> >>>
> >>>
> >>>
> >>> Of further interest is the question of whether this
> transplacental
> >>> transmission could also occur in other reservoir animals or even
> in
> >>> human leishmaniasis ? I recall the description of such
> transmission
> >>> in human cases in some very early literature, but that has been
> >>> always considered as unlikely or extremely rare, more as a
> >>> hypothesis
> >>> than reality. This issue may have been addressed in more recent
> >>> epidemiological studies of VL familial clustering in
> >>> well-established
> >>> endemic sites ? Congenital transmission might escape our
> attention,
> >>> should the outcome be largely asymptomatic ?
> >>>
> >>>
> >>>
> >>> KP
> >>>
> >>>
> >>>
> >>> ________________________________
> >>>
> >>> From: Jennie Blackwell [mailto:jmb37 at cam.ac.uk [29]]
> >>> Sent: Wednesday, October 05, 2011 6:46 PM
> >>> To: Chang, Kwang-Poo
> >>> Cc: Petersen, Christine A [V PTH]; TECSA - Luiz Ristow; John
> David;
> >>> leish-l at lineu.icb.usp.br [30]
> >>> Subject: Re: [Leish-l] RES: testing vaccinated dogs for
> >>> immunopotentiation
> >>>
> >>>
> >>>
> >>> I doubt it. Treatment might but if the mum was already infected
> and
> >>> passed the parasite to the foetus I don't see how a vaccine
> would
> >>> work to clear the parasite from the foetus!
> >>>
> >>>
> >>>
> >>> Slightly different question as to whether vaccinating mums will
> >>> give
> >>> them sufficient protection to not pass the parasite to the pup
> in
> >>> utero should they get infected themselves after vaccination.
> >>>
> >>>
> >>>
> >>> Cheers all, Jennie
> >>>
> >>> Jenefer M. Blackwell
> >>>
> >>> TICHR, CCHR, UWA
> >>>
> >>> Phone: +61 8 94897910 [31]
> >>>
> >>> From my iPhone
> >>>
> >>>
> >>> On 29 Sep 2011, at 00:36, "Chang, Kwang-Poo"
> >>> wrote:
> >>>
> >>> Of interest is the question of whether vaccination would
> >>> clear
> >>> the infection of the pub, which has congenitally inherited L
> >>> infantum ?
> >>>
> >>>
> >>>
> >>> KP
> >>>
> >>>
> >>>
> >>>
> >>> ________________________________
> >>>
> >>>
> >>> From: Petersen, Christine A [V PTH]
> >>> [mailto:kalicat at iastate.edu [33]]
> >>>
> >>> Sent: Wednesday, September 28, 2011 11:23 AM
> >>> To: Chang, Kwang-Poo; TECSA - Luiz Ristow; John David
> >>> Cc: leish-l at lineu.icb.usp.br [34]; Petersen, Christine A [V PTH]
> >>> Subject: RE: [Leish-l] RES: testing vaccinated dogs for
> >>> immunopotentiation
> >>>
> >>>
> >>>
> >>> The reference for this article is:
> >>>
> >>> http://www.ncbi.nlm.nih.gov/pubmed/21532741 [36]
> >>>
> >>> As it was published in a PLoS journal its free access to all.
> >>>
> >>> Based on our studies and recent ones from Brazil, I do
> >>> believe
> >>> that to remove Leish from the canine reservoir, transmission
> from
> >>> mom
> >>> to pup will need to be addressed.
> >>>
> >>> Christy Petersen
> >>>
> >>>
> >>>
> >>> From: Chang, Kwang-Poo
> >>> [mailto:KwangPoo.Chang at rosalindfranklin.edu [37]]
> >>> Sent: Wednesday, September 28, 2011 10:20 AM
> >>> To: TECSA - Luiz Ristow; John David
> >>> Cc: leish-l at lineu.icb.usp.br [38]; Petersen, Christine A [V PTH]
> >>> Subject: RE: [Leish-l] RES: testing vaccinated dogs for
> >>> immunopotentiation
> >>>
> >>>
> >>>
> >>> Christine Petersen published an article about transplacental
> >>> transmission of L infantum in the USA canine leishmaniasis. I
> just
> >>> wonder about the implication of this finding in considering
> >>> vaccination against the disease transmitted this way ?
> >>>
> >>>
> >>>
> >>> KP
> >>>
> >>>
> >>>
> >>>
> >>> ________________________________
> >>>
> >>>
> >>> From:
> >>> leish-l-bounces at lineu.icb.usp.br [40]
> >>> [mailto:leish-l-bounces at lineu.icb.usp.br [41]]
> >>> On Behalf
> >>> Of
> >>> TECSA - Luiz Ristow
> >>> Sent: Wednesday, September 28, 2011 9:08 AM
> >>> To: 'John David'
> >>> Cc:
> >>> leish-l at lineu.icb.usp.br [44]
> >>> Subject: [Leish-l] RES: testing vaccinated dogs for
> >>> immunopotentiation
> >>>
> >>>
> >>>
> >>> Hi !
> >>>
> >>>
> >>>
> >>> There are these papers about
> >>>
> >>> These need a very critical reading to discuss
> >>>
> >>> This discussion with all about the matter and these papers is
> >>> very welcome! (at least for me!)
> >>>
> >>> Regards for all
> >>>
> >>> Luiz Ristow
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> De:
> >>> leish-l-bounces at lineu.icb.usp.br [46]
> >>> [mailto:leish-l-bounces at lineu.icb.usp.br [47]]
> >>> Em nome de
> >>> John David
> >>> Enviada em: segunda-feira, 26 de setembro de 2011 18:44
> >>> Para: Dr GR Rajasekariah
> >>> Cc:
> >>> leish-l at lineu.icb.usp.br [50];
> >>> Carlos Gouvea; hubert mazure;
> >>> smithyman at cellabs.com.au [52]
> >>> Assunto: Re: [Leish-l] testing vaccinated dogs for
> >>> immunopotentiation
> >>>
> >>>
> >>>
> >>> I think that for any vaccine developed to protect dogs
> >>> against
> >>> VL, but which is also meant to prevent transmission of VL to
> >>> humans,
> >>> the developers should show that after the vaccinated dog has
> been
> >>> challenged with Leishmania, it does not transmit Leishmania to
> sand
> >>> flies.
> >>>
> >>> John R David, M.D.
> >>>
> >>> Richard Pearson Strong Professor Emeritus
> >>>
> >>> Department of Immunology and Infectious Diseases
> >>>
> >>> Harvard School of Public Health
> >>>
> >>> Professor of Medicine, Harvard Medical School
> >>>
> >>> 300 W. 23rd Street, Apt. 13K
> >>>
> >>> New York, NY, 10011
> >>>
> >>> Tel: 212 414 8646 [53]
> >>>
> >>> Email:
> >>> jdavid at hsph.harvard.edu [55]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> On Sep 19, 2011, at 12:04 AM, Dr GR Rajasekariah wrote:
> >>>
> >>>
> >>>
> >>> Hello EveryOne,
> >>> I am responding to the topic on European VL Dog vaccine.
> >>> It is a great challenge in devising a protective vaccine
> >>> against visceral leishmaniasis in dogs. This point equally
> applies
> >>> the same challenge for human situation.
> >>> Because Th-2 response is so dominant during VL infection,
> >>> modulating Th-2 into Th-1 response is a big challenge to
> >>> immunologists.
> >>>
> >>> Key points lies in the presentation of appropriate antigen in
> >>> appropriate dose to stimulate the Th-1 dependent protective
> immune
> >>> response.
> >>> I understand several vaccines are in the market and real
> >>> efficacy of these vaccines will come out once introduced to
> field
> >>> conditions.
> >>>
> >>> I just wanted to inform you that we have a suitable antibody
> >>> kit for testing the immunopotentiation in dogs following
> >>> vaccination
> >>> of dogs.
> >>> Our assay is based on the released promastigote antigens.
> >>> It is a highly sensitive assay.
> >>> Currently we supply reagents for determination of total IgG
> >>> antibodies in serum.
> >>> If any particular group is interested then we are able to
> >>> provide appropriate reagent for detection of specific IgG2 and
> >>> other
> >>> isotype specific antibody detection.
> >>> Because our antibody detection ELISA is based on the
> >>> exo-antigens such an ELISA would be of exceptional type for
> >>> measuring
> >>> antibody response in vaccinated animals.
> >>> Highly suitable for diagnosing dogs responded to vaccines.
> >>>
> >>> Recently I came to know that some of commercial kits were
> >>> found to be not useful for detecting seroconversion in dogs
> >>> vaccinated with FML vaccine (Leish-Immune) in Brazil.
> >>> Because we use released antigens in our kit, any such
> >>> problems
> >>> will overcome if they use Canine Leish IgG CELISA (Manufacturer
> >>> Cellabs Pty Ltd Brookvale NSW Australia email
> >>> sales at cellabs.com.au [57]).
> >>> If any one is interested to know more about our antibody
> >>> detection ELISA based on exo-antigens please contact us.
> >>>
> >>> This is for your kind information.
> >>>
> >>> Dr GR Rajasekariah
> >>> Sydney
> >>> Australia
> >>> raj at cellabs.com.au [59]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> ----- Original Message ----- From: <
> >>>
> >>> leish-l-request at lineu.icb.usp.br [61]>
> >>> To: <
> >>> leish-l at lineu.icb.usp.br [63]>
> >>> Sent: Wednesday, August 10, 2011 5:18 PM
> >>> Subject: Leish-l Digest, Vol 44, Issue 3
> >>>
> >>> Send Leish-l mailing list submissions to
> >>>
> >>>
> >>> leish-l at lineu.icb.usp.br [65]
> >>>
> >>>
> >>>
> >>> To subscribe or unsubscribe via the World Wide Web,
> >>> visit
> >>>
> >>>
> >>>
> >>> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [67]
> >>>
> >>> or, via email, send a message with subject or body
> >>> 'help' to
> >>>
> >>>
> >>> leish-l-request at lineu.icb.usp.br [69]
> >>>
> >>>
> >>>
> >>> You can reach the person managing the list at
> >>>
> >>>
> >>> leish-l-owner at lineu.icb.usp.br [71]
> >>>
> >>>
> >>>
> >>> When replying, please edit your Subject line so it is
> >>> more specific
> >>>
> >>> than "Re: Contents of Leish-l digest..."
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> Today's Topics:
> >>>
> >>>
> >>>
> >>> 1. European VL Dog Vaccine - CaniLeish?: (jeffrey
> >>> shaw)
> >>>
> >>> 2. Re: FW: Leishmaniasis Pathology Network (Moazzem
> >>> Hossain)
> >>>
> >>> 3. Re: FW: Leishmaniasis Pathology Network (Moazzem
> >>> Hossain)
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> ---------------------------------------------------------------------
> >>> -
> >>>
> >>>
> >>>
> >>> Message: 1
> >>>
> >>> Date: Tue, 9 Aug 2011 15:18:44 +0000
> >>>
> >>> From: jeffrey shaw <
> >>> jayusp at hotmail.com [73]>
> >>>
> >>> Subject: [Leish-l] European VL Dog Vaccine -
> >>> CaniLeish?:
> >>>
> >>> To: Leish-L <
> >>> leish-l at lineu.icb.usp.br [75]>
> >>>
> >>> Message-ID: <
> >>>
> >>> COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl>
> >>>
> >>> Content-Type: text/plain; charset="windows-1252"
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> CaniLeish?:
> >>>
> >>> The European Commission granted a marketing
> >>> authorisation valid throughout the European Union, for CaniLeish
> to
> >>> Virbac S.A. on 14/03/2011.
> >>>
> >>> This vaccine, CaniLeish?, will initially be launched
> >>> in Portugal at the end of the first half of 2011. This will be
> >>> followed rapidly by launches in other countries in the endemic
> >>> area:
> >>> Spain, France, Greece and Italy (not in chronological order).
> This
> >>> roll-out takes account of the geographical prevalence of the
> >>> disease
> >>> and the time required to build vaccine production up to full
> >>> capacity. The launch in Northern European countries from where
> >>> there
> >>> is a flow of summer visitors to the endemic area will be part of
> a
> >>> second phase.
> >>>
> >>> The basis of this vaccine are excreted proteins
> >>> plus
> >>> a saponin adjuvant purified from Quil-A. Its efficacy was
> >>> determined
> >>> in a
> >>> 2 year open field trial.
> >>>
> >>> The vaccine is given to dogs as three injections,
> >>> three weeks apart, under the skin. The first injection can be
> given
> >>> from six months of age, the second injection is given three
> weeks
> >>> later and the third three weeks from the second one. Afterward a
> >>> single ?booster?
> >>> should be given every year to maintain protection.
> >>>
> >>> -------------- next part --------------
> >>>
> >>> An HTML attachment was scrubbed...
> >>>
> >>> URL: <
> >>>
> >>> >> f5e
> >>> /attachment-0001.htm>
> >>>
> >>>
> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f
> [78]
> >>> 5e/
> >>> attachment-0001.htm>
> >>>
> >>>
> >>>
> >>> ------------------------------
> >>>
> >>>
> >>>
> >>> Message: 2
> >>>
> >>> Date: Wed, 10 Aug 2011 13:07:17 +0600
> >>>
> >>> From: Moazzem Hossain <
> >>>
> >>> directordcbd at gmail.com [80]>
> >>>
> >>> Subject: Re: [Leish-l] FW: Leishmaniasis Pathology
> >>> Network
> >>>
> >>> To: jeffrey shaw <
> >>> jayusp at hotmail.com [82]>, "Prof. Paul Kaye"
> >>>
> >>> < paul.kaye at york.ac.uk [84]>
> >>>
> >>> Cc: "Prof. Dr. Moazzem Hossain" <
> >>>
> >>> profdrmoazzemhossain at gmail.com [86]>,
> >>>
> >>> Leish-L <
> >>> leish-l at lineu.icb.usp.br [88]>
> >>>
> >>> Message-ID:
> >>>
> >>> <
> >>>
> >>> >> l.c
> >>> om>
> >>>
> CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.co
> [90]
> >>> om> m>
> >>>
> >>> Content-Type: text/plain; charset=windows-1252
> >>>
> >>>
> >>>
> >>> 10 Aug 2011
> >>>
> >>>
> >>>
> >>> Dear Professor Paul Kaye,
> >>>
> >>>
> >>>
> >>> Thank you for your email. Please find attached our
> >>> supportive letter
> >>>
> >>> of interest for Leishmaniasis Pathology Network.
> >>>
> >>> Looking forward for your kind response.
> >>>
> >>>
> >>>
> >>> Best regards.
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> --
> >>>
> >>> *Prof. Dr. Moazzem Hossain *
> >>>
> >>> Ex - Director Disease Control
> >>>
> >>> Ministry of Health & Family Welfare
> >>>
> >>> Government of Bangladesh
> >>>
> >>> *Mailing address*:
> >>>
> >>> Founder Chairman and Project Director
> >>>
> >>> Institute of Allergy & Clinical Immunology of
> >>> Bangladesh
> >>> (IACIB)
> >>>
> >>> Room 4 - 5 (2nd Floor), Green Super Market, Green
> >>> Road
> >>>
> >>> Dhaka -1205, Bangladesh.
> >>>
> >>> Phone:880-2-8115646 (O )
> >>>
> >>> 880-1715038551(Mobile)
> >>>
> >>> Email:
> >>> directordcbd at gmail.com [92]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> On 8/9/11, jeffrey shaw <
> >>> jayusp at hotmail.com [94]> wrote:
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> Date: Tue, 9 Aug 2011 11:58:52 +0100
> >>>
> >>> From:
> >>> paul.kaye at york.ac.uk [96]
> >>>
> >>>
> >>>
> >>> Subject: Leishmaniasis Pathology Network
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> Dear all,
> >>>
> >>> Invitation to participate in a global
> >>> pathology
> >>>
> >>> network for
> >>>
> >>> research and training in leishmaniasis
> >>> (LeishPathNet)
> >>>
> >>> You may recall the Dormy House meeting in
> >>> 2008
> >>>
> >>> and some of
> >>>
> >>> the plans we put forward? Over
> >>>
> >>> the past
> >>>
> >>> couple years, I have also spoken more to
> >>> a
> >>> few of you about one
> >>>
> >>> idea that was
> >>>
> >>> formulated at Dormy, namely of setting
> >>> up
> >>> a digital pathology
> >>>
> >>> network. I have
> >>>
> >>> also had numerous discussions with the
> >>> major equipment
> >>>
> >>> manufacturers to see if
> >>>
> >>> any of them would be supportive of
> >>> helping
> >>> us to develop such an
> >>>
> >>> initiative. There have
> >>>
> >>> been two major
> >>>
> >>> develoments recently. First,
> >>>
> >>> Carl Zeiss
> >>>
> >>> is willing to work with us to set up an
> >>> integrated global digital
> >>>
> >>> pathology
> >>>
> >>> network (providing a significant
> >>> financial
> >>> and technical
> >>>
> >>> contribution) and
> >>>
> >>> second, the Wellcome Trust is willing to
> >>> review a pre-proposal to
> >>>
> >>> fund the
> >>>
> >>> initiative through their new Biomedical
> >>> Resources Grant scheme
> >>>
> >>> (
> >>>
> >>> >> /St rategic-awards-and-initiatives/wtdv031727.htm>
> >>>
> >>>
> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/
> [98]
> >>> Str
> >>> ategic-awards-and-initiatives/wtdv031727.htm)
> >>>
> >>> .
> >>>
> >>> I have attached an outline of the project
> >>> that
> >>>
> >>> I had sent to
> >>>
> >>> the Trust for their initial views, which
> >>> I
> >>> think is reasonably
> >>>
> >>> self-explanatory.
> >>>
> >>> They appeared very
> >>>
> >>> enthusiastic! The main
> >>>
> >>> question now is whether enough of
> >>>
> >>> you are still supportive? [ I will also
> >>> be
> >>> sending this email to
> >>>
> >>> others, but please feel free to
> >>> circulate
> >>> ]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> I think the
> >>>
> >>> project will be
> >>>
> >>> challenging, but success could have a
> >>> real impact on the way we
> >>>
> >>> conduct
> >>>
> >>> business. It should serve not only as
> >>> a
> >>> vehicle to enhance
> >>>
> >>> research in
> >>>
> >>> leishmaniasis, but the model would be
> >>> equally applicable across
> >>>
> >>> a broad range
> >>>
> >>> of diseases and global challenges
> >>> (with
> >>> leishmaniasis setting
> >>>
> >>> the pace).
> >>>
> >>> If we wish to
> >>>
> >>> proceed, the requirements
> >>>
> >>> are that we submit a pre-proposal to
> >>> the
> >>> Trust by Oct 18th 2011.
> >>>
> >>> This pre-proposal is short (4 sections
> >>> of
> >>> 350 words) and
> >>>
> >>> requires
> >>>
> >>> letters of support from the community.
> >>>
> >>> If you are
> >>>
> >>> supportive of the idea that
> >>>
> >>> we try to take this forward (and there
> >>> is plenty of scope for
> >>>
> >>> later iteration
> >>>
> >>> of the detail), I would be grateful if
> >>> you could please provide
> >>>
> >>> me with a
> >>>
> >>> letter of support by September
> >>>
> >>> 12th
> >>>
> >>> 2011, indicating whether you would
> >>> like to be a network
> >>>
> >>> partner if the bid
> >>>
> >>> is successful. You could
> >>>
> >>> also be
> >>>
> >>> supportive but not wish to become
> >>> directly involved at this
> >>>
> >>> stage, and such
> >>>
> >>> letters are equally valuable. Your
> >>> letter might also stress the
> >>>
> >>> added value
> >>>
> >>> that the network could provide, its
> >>> importance for research and
> >>>
> >>> training and/or
> >>>
> >>> for progressing the translational
> >>> agenda.
> >>>
> >>> It would also be an opportunity to
> >>> indicate whether your
> >>>
> >>> group (or
> >>>
> >>> institute, if multiple groups) would
> >>> be
> >>> interested in bidding to
> >>>
> >>> be one of the
> >>>
> >>> initial ?designated laboratories?.
> >>>
> >>> If there is
> >>>
> >>> sufficient support to
> >>>
> >>> proceed and if subsequently the
> >>> pre-proposal is successful (we
> >>>
> >>> will know on 22nd
> >>>
> >>> Nov), then I will need a few
> >>> volunteers
> >>> to help finalise the
> >>>
> >>> full proposal,
> >>>
> >>> which will be due on Jan 26th 2012.
> >>>
> >>> A funding decision will be made on May
> >>> 26th
> >>>
> >>> 2012.
> >>>
> >>> Best wishes
> >>>
> >>> and of course I am happy to
> >>>
> >>> discuss any points further (though I
> >>> will be out of the UK from
> >>>
> >>> Aug 10 ?Sept
> >>>
> >>> 12)
> >>>
> >>> Paul
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> --
> >>>
> >>> Professor Paul Kaye, Ph.D., FRCPath.
> >>>
> >>> Deputy Dean (Research), Hull York Medical
> >>> School, and
> >>>
> >>> Director, Centre for Immunology and Infection
> >>>
> >>> Department of Biology and Hull York Medical
> >>> School
> >>>
> >>> University of York
> >>>
> >>> Wentworth Way
> >>>
> >>> York YO10 5YW
> >>>
> >>> United Kingdom
> >>>
> >>>
> >>>
> >>> Tel: +44 (0)1904 328840 [99]
> >>>
> >>> Fax: +44 (0)1904 328844 [100]
> >>>
> >>> Email:
> >>> paul.kaye at york.ac.uk [102] <
> >>> mailto:paul.kaye at york.ac.uk [104]>
> >>>
> >>>
> >>>
> >>> Centre Administrator and PA: Elizabeth
> >>> Greensted
> >>>
> >>> Tel: 01904 328845
> >>>
> >>> Email:
> >>> liz.greensted at york.ac.uk [106] <
> >>> mailto:liz.greensted at york.ac.uk [108]>
> >>>
> >>>
> >>>
> >>> Centre Email:
> >>> cii at york.ac.uk [110] < mailto:cii at york.ac.uk [112]>
> >>>
> >>>
> >>>
> >>> Centre website:
> >>> http://www.york.ac.uk/cii [114]
> >>>
> >>>
> >>>
> >>> Times Higher Education University of the Year
> >>> 2010
> >>>
> >>>
> >>>
> >>> Email disclaimer:
> >>>
> >>> http://www.york.ac.uk/docs/disclaimer/email.htm [116]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> ------------------------------
> >>>
> >>>
> >>>
> >>> Message: 3
> >>>
> >>> Date: Wed, 10 Aug 2011 13:06:47 +0600
> >>>
> >>> From: Moazzem Hossain <
> >>>
> >>> directordcbd at gmail.com [118]>
> >>>
> >>> Subject: Re: [Leish-l] FW: Leishmaniasis Pathology
> >>> Network
> >>>
> >>> To: jeffrey shaw <
> >>> jayusp at hotmail.com [120]>, "Prof. Paul Kaye"
> >>>
> >>> < paul.kaye at york.ac.uk [122]>
> >>>
> >>> Cc: "Prof. Dr. Moazzem Hossain" <
> >>>
> >>> profdrmoazzemhossain at gmail.com [124]>,
> >>>
> >>> Leish-L <
> >>> leish-l at lineu.icb.usp.br [126]>
> >>>
> >>> Message-ID:
> >>>
> >>> <
> >>>
> >>> >> l.c
> >>> om>
> >>>
> CAE-TCmQNUkZdNE5w+Z20bjLC-=vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.co
> [128]
> >>> om> CAE-TCmQNUkZdNE5w+m>
> >>>
> >>> Content-Type: text/plain; charset="windows-1252"
> >>>
> >>>
> >>>
> >>> 10 Aug 2011
> >>>
> >>>
> >>>
> >>> Dear Professor Paul Kaye,
> >>>
> >>>
> >>>
> >>> Thank you for your email. Please find attached our
> >>> supportive letter
> >>>
> >>> of interest for Leishmaniasis Pathology Network.
> >>>
> >>> Looking forward for your kind response.
> >>>
> >>>
> >>>
> >>> Best regards.
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> --
> >>>
> >>> *Prof. Dr. Moazzem Hossain *
> >>>
> >>> Ex - Director Disease Control
> >>>
> >>> Ministry of Health & Family Welfare
> >>>
> >>> Government of Bangladesh
> >>>
> >>> *Mailing address*:
> >>>
> >>> Founder Chairman and Project Director
> >>>
> >>> Institute of Allergy & Clinical Immunology of
> >>> Bangladesh
> >>> (IACIB)
> >>>
> >>> Room 4 - 5 (2nd Floor), Green Super Market, Green
> >>> Road
> >>>
> >>> Dhaka -1205, Bangladesh.
> >>>
> >>> Phone:880-2-8115646 (O )
> >>>
> >>> 880-1715038551(Mobile)
> >>>
> >>> Email:
> >>> directordcbd at gmail.com [130]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> On 8/9/11, jeffrey shaw <
> >>> jayusp at hotmail.com [132]> wrote:
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> Date: Tue, 9 Aug 2011 11:58:52 +0100
> >>>
> >>> From:
> >>> paul.kaye at york.ac.uk [134]
> >>>
> >>>
> >>>
> >>> Subject: Leishmaniasis Pathology Network
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> Dear all,
> >>>
> >>> Invitation to participate in a global
> >>> pathology
> >>>
> >>> network for
> >>>
> >>> research and training in leishmaniasis
> >>> (LeishPathNet)
> >>>
> >>> You may recall the Dormy House meeting in
> >>> 2008
> >>>
> >>> and some of
> >>>
> >>> the plans we put forward? Over
> >>>
> >>> the past
> >>>
> >>> couple years, I have also spoken more to
> >>> a
> >>> few of you about one
> >>>
> >>> idea that was
> >>>
> >>> formulated at Dormy, namely of setting
> >>> up
> >>> a digital pathology
> >>>
> >>> network. I have
> >>>
> >>> also had numerous discussions with the
> >>> major equipment
> >>>
> >>> manufacturers to see if
> >>>
> >>> any of them would be supportive of
> >>> helping
> >>> us to develop such an
> >>>
> >>> initiative. There have
> >>>
> >>> been two major
> >>>
> >>> develoments recently. First,
> >>>
> >>> Carl Zeiss
> >>>
> >>> is willing to work with us to set up an
> >>> integrated global digital
> >>>
> >>> pathology
> >>>
> >>> network (providing a significant
> >>> financial
> >>> and technical
> >>>
> >>> contribution) and
> >>>
> >>> second, the Wellcome Trust is willing to
> >>> review a pre-proposal to
> >>>
> >>> fund the
> >>>
> >>> initiative through their new Biomedical
> >>> Resources Grant scheme
> >>>
> >>> (
> >>>
> >>> >> /St rategic-awards-and-initiatives/wtdv031727.htm>
> >>>
> >>>
> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/
> [136]
> >>> Str
> >>> ategic-awards-and-initiatives/wtdv031727.htm)
> >>>
> >>> .
> >>>
> >>> I have attached an outline of the project
> >>> that
> >>>
> >>> I had sent to
> >>>
> >>> the Trust for their initial views, which
> >>> I
> >>> think is reasonably
> >>>
> >>> self-explanatory.
> >>>
> >>> They appeared very
> >>>
> >>> enthusiastic! The main
> >>>
> >>> question now is whether enough of
> >>>
> >>> you are still supportive? [ I will also
> >>> be
> >>> sending this email to
> >>>
> >>> others, but please feel free to
> >>> circulate
> >>> ]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> I think the
> >>>
> >>> project will be
> >>>
> >>> challenging, but success could have a
> >>> real impact on the way we
> >>>
> >>> conduct
> >>>
> >>> business. It should serve not only as
> >>> a
> >>> vehicle to enhance
> >>>
> >>> research in
> >>>
> >>> leishmaniasis, but the model would be
> >>> equally applicable across
> >>>
> >>> a broad range
> >>>
> >>> of diseases and global challenges
> >>> (with
> >>> leishmaniasis setting
> >>>
> >>> the pace).
> >>>
> >>> If we wish to
> >>>
> >>> proceed, the requirements
> >>>
> >>> are that we submit a pre-proposal to
> >>> the
> >>> Trust by Oct 18th 2011.
> >>>
> >>> This pre-proposal is short (4 sections
> >>> of
> >>> 350 words) and
> >>>
> >>> requires
> >>>
> >>> letters of support from the community.
> >>>
> >>> If you are
> >>>
> >>> supportive of the idea that
> >>>
> >>> we try to take this forward (and there
> >>> is plenty of scope for
> >>>
> >>> later iteration
> >>>
> >>> of the detail), I would be grateful if
> >>> you could please provide
> >>>
> >>> me with a
> >>>
> >>> letter of support by September
> >>>
> >>> 12th
> >>>
> >>> 2011, indicating whether you would
> >>> like to be a network
> >>>
> >>> partner if the bid
> >>>
> >>> is successful. You could
> >>>
> >>> also be
> >>>
> >>> supportive but not wish to become
> >>> directly involved at this
> >>>
> >>> stage, and such
> >>>
> >>> letters are equally valuable. Your
> >>> letter might also stress the
> >>>
> >>> added value
> >>>
> >>> that the network could provide, its
> >>> importance for research and
> >>>
> >>> training and/or
> >>>
> >>> for progressing the translational
> >>> agenda.
> >>>
> >>> It would also be an opportunity to
> >>> indicate whether your
> >>>
> >>> group (or
> >>>
> >>> institute, if multiple groups) would
> >>> be
> >>> interested in bidding to
> >>>
> >>> be one of the
> >>>
> >>> initial ?designated laboratories?.
> >>>
> >>> If there is
> >>>
> >>> sufficient support to
> >>>
> >>> proceed and if subsequently the
> >>> pre-proposal is successful (we
> >>>
> >>> will know on 22nd
> >>>
> >>> Nov), then I will need a few
> >>> volunteers
> >>> to help finalise the
> >>>
> >>> full proposal,
> >>>
> >>> which will be due on Jan 26th 2012.
> >>>
> >>> A funding decision will be made on May
> >>> 26th
> >>>
> >>> 2012.
> >>>
> >>> Best wishes
> >>>
> >>> and of course I am happy to
> >>>
> >>> discuss any points further (though I
> >>> will be out of the UK from
> >>>
> >>> Aug 10 ?Sept
> >>>
> >>> 12)
> >>>
> >>> Paul
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> --
> >>>
> >>> Professor Paul Kaye, Ph.D., FRCPath.
> >>>
> >>> Deputy Dean (Research), Hull York Medical
> >>> School, and
> >>>
> >>> Director, Centre for Immunology and Infection
> >>>
> >>> Department of Biology and Hull York Medical
> >>> School
> >>>
> >>> University of York
> >>>
> >>> Wentworth Way
> >>>
> >>> York YO10 5YW
> >>>
> >>> United Kingdom
> >>>
> >>>
> >>>
> >>> Tel: +44 (0)1904 328840 [137]
> >>>
> >>> Fax: +44 (0)1904 328844 [138]
> >>>
> >>> Email:
> >>> paul.kaye at york.ac.uk [140] <
> >>> mailto:paul.kaye at york.ac.uk [142]>
> >>>
> >>>
> >>>
> >>> Centre Administrator and PA: Elizabeth
> >>> Greensted
> >>>
> >>> Tel: 01904 328845
> >>>
> >>> Email:
> >>> liz.greensted at york.ac.uk [144] <
> >>> mailto:liz.greensted at york.ac.uk [146]>
> >>>
> >>>
> >>>
> >>> Centre Email:
> >>> cii at york.ac.uk [148] < mailto:cii at york.ac.uk [150]>
> >>>
> >>>
> >>>
> >>> Centre website:
> >>> http://www.york.ac.uk/cii [152]
> >>>
> >>>
> >>>
> >>> Times Higher Education University of the Year
> >>> 2010
> >>>
> >>>
> >>>
> >>> Email disclaimer:
> >>>
> >>> http://www.york.ac.uk/docs/disclaimer/email.htm [154]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> -------------- next part --------------
> >>>
> >>> A non-text attachment was scrubbed...
> >>>
> >>> Name: Letter Leish UK.doc
> >>>
> >>> Type: application/msword
> >>>
> >>> Size: 46080 bytes
> >>>
> >>> Desc: not available
> >>>
> >>> URL: <
> >>>
> >>> >> e6a
> >>> /attachment.doc>
> >>>
> >>>
> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae
> [156]
> >>> 6a/
> >>> attachment.doc>
> >>>
> >>>
> >>>
> >>> ------------------------------
> >>>
> >>>
> >>>
> >>> _______________________________________________
> >>>
> >>> Leish-l mailing list
> >>>
> >>>
> >>> Leish-l at lineu.icb.usp.br [158]
> >>>
> >>>
> >>>
> >>> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [160]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> End of Leish-l Digest, Vol 44, Issue 3
> >>>
> >>> **************************************
> >>>
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> =======
> >>> Email scanned by PC Tools - No viruses or spyware found.
> >>> (Email Guard: 7.0.0.26, Virus/Spyware Database: 6.18330)
> >>> http://www.pctools.com/ [162]
> >>> =======
> >>> _______________________________________________
> >>> Leish-l mailing list
> >>> Leish-l at lineu.icb.usp.br [164]
> >>>
> >>> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [166]
> >>>
> >>>
> >>>
> >>>
> >>>
> >>> _______________________________________________
> >>> Leish-l mailing list
> >>> Leish-l at lineu.icb.usp.br [167]
> >>> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [168]
> >>>
> >>>
> >>
> >>
> >>
> >>
> >> _______________________________________________
> >> Leish-l mailing list
> >> Leish-l at lineu.icb.usp.br [169]
> >> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [170]
> >>
> >> --
> >> This message has been scanned for viruses and dangerous content
> by
> >> MailScanner, and is believed to be clean.
> >>
> >>
> >>
>
> ######################################################################
> >> ############### This e-mail message has been scanned for Viruses
> and
> >> Content and cleared by MailMarshal
> >>
> >>
>
> ######################################################################
> >> ############### _______________________________________________
> >> Leish-l mailing list
> >> Leish-l at lineu.icb.usp.br [171]
> >> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [172]
> >>
> >>
> >> _______________________________________________
> >> Leish-l mailing list
> >> Leish-l at lineu.icb.usp.br [173]
> >> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [174]
> >>
> >
> >
> >
> > _______________________________________________
> > Leish-l mailing list
> > Leish-l at lineu.icb.usp.br [175]
> > http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [176]
> > _______________________________________________
> > Leish-l mailing list
> > Leish-l at lineu.icb.usp.br [177]
> > http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [178]
>
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br [179]
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [180]
>
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br [181]
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l [182]
>
> --
>
> CARLOS H. N. COSTA, MD, DSC.
>
> SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
>
> (BRAZILIAN SOCIETY OF TROPICAL MEDICINE)
>
> PRESIDENT
>
> UNIVERSIDADE FEDERAL DO PIAUÍ
>
> INSTITUTO DE DOENÇAS TROPICAIS NATAN PORTELLA
>
> RUA ARTUR DE VASCONCELOS 151-SUL
>
> 64001-450 TERESINA-PI
>
> BRAZIL
>
> TELEPHONES: +55 86 3221-3413 (WORK); +55 86 8838-3303 (MOBILE).
>
> Aviso: As informações contidas nesta mensagem são CONFIDENCIAIS,
> protegidas pelo sigilo legal, por direitos autorais e destinadas
> exclusivamente à pessoa ou organização para a qual a mensagem foi
> destinada.
>
> Warning: This message is meant only for the intended recipient of the
> transmission. It is forbidden any unauthorized use, alteration,
> reproduction and distribution. If you are not the correct recipient,
> please notify us immediately by return e-mail and delete this message
> from your system.
>
>
>
> Links:
> ------
> [1] mailto:KwangPoo.Chang at rosalindfranklin.edu
> [2] mailto:leish-l-bounces at lineu.icb.usp.br
> [3] mailto:leish-l-bounces at lineu.icb.usp.br
> [4] mailto:mauro.marzochi at ipec.fiocruz.br
> [5] mailto:leish-l at lineu.icb.usp.br
> [6] mailto:leish-l-bounces at lineu.icb.usp.br
> [7] mailto:leish-l-bounces at lineu.icb.usp.br
> [8] mailto:leish-l at lineu.icb.usp.br
> [9] mailto:jayusp at hotmail.com
> [10] mailto:orin.courtenay at warwick.ac.uk
> [11] http://www2.warwick.ac.uk/fac/sci/lifesci/people/ocourtenay/
> [12] https://files.warwick.ac.uk/orincourtenay/sendto
> [13] mailto:leish-l-bounces at lineu.icb.usp.br
> [14] mailto:leish-l-bounces at lineu.icb.usp.br
> [15] mailto:leish-l at lineu.icb.usp.br
> [16] mailto:leish-l-bounces at lineu.icb.usp.br
> [17] mailto:leish-l-bounces at lineu.icb.usp.br
> [18] mailto:leish-l at lineu.icb.usp.br
> [19] mailto:KwangPoo.Chang at rosalindfranklin.edu
> [20] mailto:leish-l-bounces at lineu.icb.usp.br
> [21] mailto:leish-l-bounces at lineu.icb.usp.br
> [22] mailto:leish-l at lineu.icb.usp.br
> [23] http://www.vawatchdog.org/07/nf07/nfJUN07/nf062907-3.htm
> [24] http://www.leishmaniasis.us/Leish.html
> [25] mailto:leish-l-bounces at lineu.icb.usp.br
> [26] mailto:leish-l-bounces at lineu.icb.usp.br
> [27] mailto:leish-l at lineu.icb.usp.br
> [28] mailto:KwangPoo.Chang at rosalindfranklin.edu
> [29] mailto:jmb37 at cam.ac.uk
> [30] mailto:leish-l at lineu.icb.usp.br
> [31] http://correio.ipec.fiocruz.br/tel:%2B61%208%2094897910
> [32] mailto:KwangPoo.Chang at rosalindfranklin.edu
> [33] mailto:kalicat at iastate.edu
> [34] mailto:leish-l at lineu.icb.usp.br
> [35] http://www.ncbi.nlm.nih.gov/pubmed/21532741
> [36] http://www.ncbi.nlm.nih.gov/pubmed/21532741
> [37] mailto:KwangPoo.Chang at rosalindfranklin.edu
> [38] mailto:leish-l at lineu.icb.usp.br
> [39] mailto:leish-l-bounces at lineu.icb.usp.br
> [40] mailto:leish-l-bounces at lineu.icb.usp.br
> [41] mailto:leish-l-bounces at lineu.icb.usp.br
> [42] mailto:5bmailto%3Aleish-l-bounces at lineu.icb.usp.br
> [43] mailto:leish-l at lineu.icb.usp.br
> [44] mailto:leish-l at lineu.icb.usp.br
> [45] mailto:leish-l-bounces at lineu.icb.usp.br
> [46] mailto:leish-l-bounces at lineu.icb.usp.br
> [47] mailto:leish-l-bounces at lineu.icb.usp.br
> [48] mailto:5bmailto%3Aleish-l-bounces at lineu.icb.usp.br
> [49] mailto:leish-l at lineu.icb.usp.br
> [50] mailto:leish-l at lineu.icb.usp.br
> [51] mailto:smithyman at cellabs.com.au
> [52] mailto:smithyman at cellabs.com.au
> [53] http://correio.ipec.fiocruz.br/tel:212%20414%208646
> [54] mailto:jdavid at hsph.harvard.edu
> [55] mailto:jdavid at hsph.harvard.edu
> [56] mailto:sales at cellabs.com.au
> [57] mailto:sales at cellabs.com.au
> [58] mailto:raj at cellabs.com.au
> [59] mailto:raj at cellabs.com.au
> [60] mailto:leish-l-request at lineu.icb.usp.br
> [61] mailto:leish-l-request at lineu.icb.usp.br
> [62] mailto:leish-l at lineu.icb.usp.br
> [63] mailto:leish-l at lineu.icb.usp.br
> [64] mailto:leish-l at lineu.icb.usp.br
> [65] mailto:leish-l at lineu.icb.usp.br
> [66] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [67] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [68] mailto:leish-l-request at lineu.icb.usp.br
> [69] mailto:leish-l-request at lineu.icb.usp.br
> [70] mailto:leish-l-owner at lineu.icb.usp.br
> [71] mailto:leish-l-owner at lineu.icb.usp.br
> [72] mailto:jayusp at hotmail.com
> [73] mailto:jayusp at hotmail.com
> [74] mailto:leish-l at lineu.icb.usp.br
> [75] mailto:leish-l at lineu.icb.usp.br
> [76] mailto:COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl
> [77]
> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404
> [78]
> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f
> [79] mailto:directordcbd at gmail.com
> [80] mailto:directordcbd at gmail.com
> [81] mailto:jayusp at hotmail.com
> [82] mailto:jayusp at hotmail.com
> [83] mailto:paul.kaye at york.ac.uk
> [84] mailto:paul.kaye at york.ac.uk
> [85] mailto:profdrmoazzemhossain at gmail.com
> [86] mailto:profdrmoazzemhossain at gmail.com
> [87] mailto:leish-l at lineu.icb.usp.br
> [88] mailto:leish-l at lineu.icb.usp.br
> [89] mailto:CAE-TCmS
> [90] mailto:KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.co
> [91] mailto:directordcbd at gmail.com
> [92] mailto:directordcbd at gmail.com
> [93] mailto:jayusp at hotmail.com
> [94] mailto:jayusp at hotmail.com
> [95] mailto:paul.kaye at york.ac.uk
> [96] mailto:paul.kaye at york.ac.uk
> [97]
> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes
> [98]
> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/
> [99] http://correio.ipec.fiocruz.br/tel:%2B44%20%280%291904%20328840
> [100] http://correio.ipec.fiocruz.br/tel:%2B44%20%280%291904%20328844
> [101] mailto:paul.kaye at york.ac.uk
> [102] mailto:paul.kaye at york.ac.uk
> [103] mailto:paul.kaye at york.ac.uk
> [104] mailto:paul.kaye at york.ac.uk
> [105] mailto:liz.greensted at york.ac.uk
> [106] mailto:liz.greensted at york.ac.uk
> [107] mailto:liz.greensted at york.ac.uk
> [108] mailto:liz.greensted at york.ac.uk
> [109] mailto:cii at york.ac.uk
> [110] mailto:cii at york.ac.uk
> [111] mailto:cii at york.ac.uk
> [112] mailto:cii at york.ac.uk
> [113] http://www.york.ac.uk/cii
> [114] http://www.york.ac.uk/cii
> [115] http://www.york.ac.uk/docs/disclaimer/email.htm
> [116] http://www.york.ac.uk/docs/disclaimer/email.htm
> [117] mailto:directordcbd at gmail.com
> [118] mailto:directordcbd at gmail.com
> [119] mailto:jayusp at hotmail.com
> [120] mailto:jayusp at hotmail.com
> [121] mailto:paul.kaye at york.ac.uk
> [122] mailto:paul.kaye at york.ac.uk
> [123] mailto:profdrmoazzemhossain at gmail.com
> [124] mailto:profdrmoazzemhossain at gmail.com
> [125] mailto:leish-l at lineu.icb.usp.br
> [126] mailto:leish-l at lineu.icb.usp.br
> [127] mailto:CAE-TCmQNUkZdNE5w%2BZ20bjLC-
> [128] mailto:vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.co
> [129] mailto:directordcbd at gmail.com
> [130] mailto:directordcbd at gmail.com
> [131] mailto:jayusp at hotmail.com
> [132] mailto:jayusp at hotmail.com
> [133] mailto:paul.kaye at york.ac.uk
> [134] mailto:paul.kaye at york.ac.uk
> [135]
> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes
> [136]
> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/
> [137] http://correio.ipec.fiocruz.br/tel:%2B44%20%280%291904%20328840
> [138] http://correio.ipec.fiocruz.br/tel:%2B44%20%280%291904%20328844
> [139] mailto:paul.kaye at york.ac.uk
> [140] mailto:paul.kaye at york.ac.uk
> [141] mailto:paul.kaye at york.ac.uk
> [142] mailto:paul.kaye at york.ac.uk
> [143] mailto:liz.greensted at york.ac.uk
> [144] mailto:liz.greensted at york.ac.uk
> [145] mailto:liz.greensted at york.ac.uk
> [146] mailto:liz.greensted at york.ac.uk
> [147] mailto:cii at york.ac.uk
> [148] mailto:cii at york.ac.uk
> [149] mailto:cii at york.ac.uk
> [150] mailto:cii at york.ac.uk
> [151] http://www.york.ac.uk/cii
> [152] http://www.york.ac.uk/cii
> [153] http://www.york.ac.uk/docs/disclaimer/email.htm
> [154] http://www.york.ac.uk/docs/disclaimer/email.htm
> [155]
> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2a
> [156]
> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae
> [157] mailto:Leish-l at lineu.icb.usp.br
> [158] mailto:Leish-l at lineu.icb.usp.br
> [159] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [160] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [161] http://www.pctools.com/
> [162] http://www.pctools.com/
> [163] mailto:Leish-l at lineu.icb.usp.br
> [164] mailto:Leish-l at lineu.icb.usp.br
> [165] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [166] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [167] mailto:Leish-l at lineu.icb.usp.br
> [168] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [169] mailto:Leish-l at lineu.icb.usp.br
> [170] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [171] mailto:Leish-l at lineu.icb.usp.br
> [172] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [173] mailto:Leish-l at lineu.icb.usp.br
> [174] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [175] mailto:Leish-l at lineu.icb.usp.br
> [176] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [177] mailto:Leish-l at lineu.icb.usp.br
> [178] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [179] mailto:Leish-l at lineu.icb.usp.br
> [180] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> [181] mailto:Leish-l at lineu.icb.usp.br
> [182] http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
More information about the Leish-l
mailing list